Pharmacokinetics of Nafcillin in Patients with Renal Failure
AUTOR(ES)
Diaz, Carlos R.
RESUMO
Nafcillin, a pencillinase-resistant penicillin, is frequently used for treatment of staphylococcal infections in hemodialysis patients. Despite its widespread use, there is a paucity of available data regarding the pharmacokinetics of nafcillin in hemodialysis patients. Therefore, sodium nafcillin, 25 mg/kg, was given intravenously over a 5- to 15-min period to 12 hemodialysis patients. Eleven patients were studied during dialysis, and eight of these were studied again during the interdialysis period. The initial serum half-life for nafcillin was 0.208 h during dialyses and 0.278 h between dialyses. The terminal half-life was 1.48 h during dialyses and 1.89 h between dialyses. There was no statistically significant difference between these values. These data indicate that renal failure does not appreciably affect the serum half-life of nafcillin, and hemodialysis does not accelerate the rate of clearance of nafcillin from the blood. Therefore, no modification of the usual nafcillin dosage is necessary when using this drug in hemodialysis patients.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=352160Documentos Relacionados
- Pharmacokinetics of Cefamandole in Patients with Renal Failure
- Pharmacokinetics of moxalactam in patients with renal failure and during hemodialysis.
- Pharmacokinetics of piperacillin in patients with moderate renal failure and in patients undergoing hemodialysis.
- Pharmacokinetics of Cefaclor in Normal Subjects and Patients with Chronic Renal Failure
- Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis.
